FRM
VKTX icon

Fox Run Management’s Viking Therapeutics VKTX Stock Holding History

Fox Run Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
28,315
+10,757
+61% +$347K 0.18% 148
2026
Q1 		$525K Sell
17,558
-12,538
-42% -$403K 0.09% 409
2025
Q4 		$1.06M Buy
+30,096
New +$1.07M 0.16% 190
2025
Q3 		– Sell
-37,705
Closed -$999K – 1260
2025
Q2 		$999K Buy
37,705
+4,274
+13% +$113K 0.17% 191
2025
Q1 		$807K Buy
+33,431
New +$1.06M 0.13% 278
2022
Q1 		– Sell
-11,199
Closed -$52K – 715
2021
Q4 		$52K Buy
+11,199
New +$62.8K 0.03% 439
2019
Q1 		– Sell
-10,926
Closed -$84K – 706
2018
Q4 		$84K Buy
+10,926
New +$131K 0.04% 472

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Fox Run Management's VKTX Position: Q2 2026 in Review

Fox Run Management increased its Viking Therapeutics (VKTX) stake by 61% in Q2 2026, buying an estimated $347K and bringing the position to 28,315 shares worth $1.1M. The position accounts for 0.18% of the portfolio, ranked #148.

Fox Run Management first reported a position in VKTX in Q4 2018 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Fox Run Management held 28,315 shares of Viking Therapeutics worth $1.1M as of Q2 2026.
  • Fox Run Management bought 10,757 Viking Therapeutics shares in Q2 2026, an estimated $347K.
  • Viking Therapeutics made up 0.18% of Fox Run Management's portfolio in Q2 2026, its #148 holding.
  • Fox Run Management first reported a position in Viking Therapeutics in Q4 2018 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.